Six Billion Dollars: The Number PBMs Can't Ignore
Pfizer's oncology pipeline is positioned to deliver a combined $6 billion in peak annual sales from next year’s launches alone, according to recent investor guidance. That figure, quietly cited on slide 14 of the company’s latest investor deck, has started to tilt the balance of power in contract negotiations between specialty pharmacies and pharmacy benefit managers (PBMs). For context, all new oncology therapy sales in the US this year are forecast at around $25 billion. Pfizer’s anticipated contribution isn’t just substantial. It’s a signal: PBMs’ ability to dictate access, pricing, and reimbursement for cutting-edge cancer drugs now depends on how tough they get with Pfizer in the coming months.
And the shift is already visible. Early term sheets exchanged between Pfizer and at least two of the top three PBMs show rebate asks that top 40 percent on some products, a marked increase from the 25 percent benchmark that dominated just five years ago for novel oncology launches. These numbers aren’t coming from flashy press releases. They surface in revised revenue guidance, which now assumes steeper gross-to-net deductions, and they’re echoed in the tighter margins being projected by specialty pharmacies on recent Q1 earnings calls. For a deeper examine the crosscurrents driving drug pricing this year, see RxInfo.ai.
Pipeline Details: The Unique Shape of 2025
Pfizer’s 2025 oncology calendar is unusually full. There’s the breast cancer CDK4/6 inhibitor in the adjuvant space, a HER2-directed bispecific targeting refractory GI tumors, and an oral BCL2 agent for blood cancers expected to challenge AbbVie’s Venclexta. Not just clinical complexity at play. These launches land in classes where competitive pressure is fierce, formulary access is hard-fought, and step-edit hurdles have become the default.
This time, PBMs wield more leverage. The last wave of blockbuster launches left PBMs negotiating one-off high-value drugs, but now, the specialty market is both more consolidated and more insistent on exclusive distribution. The trend is no longer hypothetical. Cigna’s Evernorth and CVS Health’s Caremark have slashed their oncology specialty networks to six to eight pharmacies, a sharp cut from 15 in 2019. As a result, specialty pharmacy contracts now carry sharper teeth, mid-contract terminations can happen if rebate guarantees slip or adherence metrics aren’t met.
Pfizer, meanwhile, is opting for a hybrid approach. Some drugs will flow through open distribution, but the biggest bets, high-touch biologics, will come with exclusive or tightly limited pharmacy deals. The company’s own filings indicate it expects at least 60 percent of its 2025 oncology revenue to channel through these exclusive or limited-distribution agreements. That setup arms PBMs with leverage to push harder on price and rebate terms. But then again, any pharmacy or pharma cut from a preferred network will lose access to a huge chunk of volume in a single stroke.
PBMs Upend Contracting: New Tactics, New Risks
In response to Pfizer’s launches, PBMs are overhauling contract models. The days when rebate percentage was the main number on the table are basically over. Contracts now come with inventive, and yes, burdensome, structures. Several PBMs are proposing tiered rebate ladders based not just on sales volume, but on documented patient outcomes. At least one major PBM has floated retroactive clawbacks if real-world progression-free survival underperforms expectations set on the label. Pfizer’s attorneys, by all accounts, are drawing hard lines against these risk-based demands for some of their biggest assets.
Payment timing is another lever. Pharmacies that once counted on reimbursement within 30 days of claims processing are now seeing timelines stretch to 45 or even 60 days when rebate disputes bubble up. Doesn’t sound huge at first, but with $6 billion riding on annual specialty launches, the working capital crunch for pharmacies is real. PBMs argue this aligns financial incentives. Specialty pharmacies say it’s just another margin squeeze, especially for independents, who can’t tap the same cash reserves as the likes of CVS or Optum.
Therapy management terms are tightening, too. The 2025 draft contracts reviewed by RxInsider consistently require more: stricter adherence tracking, mandatory digital engagement, even penalties for overnight delivery failures, fees that can hit up to $350 per shipment. Pharmacies are balking, warning these requirements could push their operating costs up by 8 to 10 percent, with little hope of recovering those expenses under current fee-for-service models.
More insight on how PBM incentives shape these negotiations is available at RxPBM.ai.
Winners, Losers, and What's Next
The stakes are obvious. For Pfizer, securing $6 billion in annual revenue across PBM-controlled networks means trading margin for unfettered access. The alternative, exclusion or relegation to step-therapy tiers, is costlier still. PBMs, flush with negotiating leverage, are extracting bigger concessions, confident that Pfizer can’t risk a slip-up in any core cancer indication.
But specialty pharmacies are most exposed. The big national chains, with robust payer relationships, are built to shoulder rebate delays and contract volatility. Regional and independent pharmacies? Not so much. Many are now warning that 2025 could trigger a wave of consolidation, or outright exits. Earnings calls from three regional chains have flagged “network optimization reviews” as a direct threat to their survival. As for employer groups and self-funded plans, changes in rebate structures might suggest lower prices on paper, but the reality is different. Transparency rarely follows, savings aren’t guaranteed to pass through. What really moves is the PBM’s spread and how network tiers are sliced and diced, details you’ll find explored at RxBenefits.ai.
The coming months will force the issue. Final PBM-Pfizer contracts will set the tone before these oncology launches hit the market. Here’s the bottom line: that $6 billion headline is more than just a number for Pfizer’s investor slides. It’s an inflection point, one already redrawing the oncology supply chain, reshuffling who gets paid, and pressing some specialty pharmacies to the brink. Will the system adapt, or just churn through another round of closures? Nobody’s pretending they know for sure.
